{"id":61030,"date":"2025-04-02T19:02:57","date_gmt":"2025-04-02T17:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/t-cell-therapy-market-research-2025-leading-players-and-sales-forecast-of-therapies-industry-trends-and-global-forecasts-to-2035-researchandmarkets-com\/"},"modified":"2025-04-02T19:02:57","modified_gmt":"2025-04-02T17:02:57","slug":"t-cell-therapy-market-research-2025-leading-players-and-sales-forecast-of-therapies-industry-trends-and-global-forecasts-to-2035-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/t-cell-therapy-market-research-2025-leading-players-and-sales-forecast-of-therapies-industry-trends-and-global-forecasts-to-2035-researchandmarkets-com\/","title":{"rendered":"T-Cell Therapy Market Research 2025: Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “T-Cell Therapy Market by Type of Therapy, Target Indication, Target Antigen, Company Size, Geographical Regions, Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe global T-cell therapy market size is estimated to grow from USD 6.5 billion in the current year to USD 20.9 billion by 2035, at a CAGR of 12% during the forecast period, till 2035.\n<\/p>\n

\nAmidst the ongoing efforts to develop more precise and effective anti-cancer therapeutics, T-cell therapies haveevolved as a promising immunotherapy that uses the body’s own immune cells to selectively eliminate tumor cells with minimal side effects. Unlike conventional therapies, immunotherapies provide several advantages, including specificity, potential reduction in off-target toxicities and improving treatment outcomes.\n<\/p>\n

\nIt is worth mentioning that in 2024, the US Food and Drug Administration approved multiple T cell therapies targeting cancer (in reverse chronological order<\/em>), such as Obecabtagene autoleucel \/ Aucatzyl (relapsed or refractory B-cell precursor acute lymphoblastic leukemia, November 2024<\/em>), Afamitresgene autoleucel \/ TECELRA (metastatic or unresectable synovial sarcoma, August 2024<\/em>) and Lifileucel \/ Amtagvi (unresectable or metastatic melanoma, February 2024<\/em>).\n<\/p>\n

\nDriven by the advantages offered by immunotherapies over conventional therapies, the increasing adoption of T-cell-based immunotherapies and the surge in demand for personalized cancer treatment, coupled with the expedited regulatory approvals, is expected to drive significant growth in the T cell therapeutics market. Moreover, as the global oncology landscape continues to evolve, advancements in T cell engineering and next-generation manufacturing technologies would drive innovation in this domain and position the market for steady growth in the forthcoming years.\n<\/p>\n

\nT-Cell Therapy Market: Key Segments<\/strong>\n<\/p>\n

\nCAR T-cell Therapy Market Holds the Largest Share of the T-Cell Therapy Market During the Forecast Period<\/strong>\n<\/p>\n

\nBased on the type of therapy, the global market is segmented into CAR-T, TCR and TIL therapies. Currently, the CAR T-cell therapy market segment captures the majority of the overall market share and is likely to dominate and drive the overall market growth. This can be attributed to the precise targeting mechanism of CAR T cell therapies that use chimeric antigen receptors to target and kill malignant cells (while minimizing damage to healthy tissues<\/em>). It is worth highlighting that the TIL therapy market segment is likely to flourish during the forecast period, owing to their versatility in targeting a wide range of cancers and encouraging clinical trial results.\n<\/p>\n

\nTherapies Targeting Melanoma Hold the Largest Share of TCR Therapies Market<\/strong>\n<\/p>\n

\nCurrently, the majority share of the TCR therapies market is captured by therapies targeting melanoma (over 95%<\/em>). This can be attributed to the fact that melanoma has a high rate of genetic mutations, leading to the production of many unique neoantigens which makes it a prime target for TCR therapies. Recently, the FDA has approved a TCR therapy (Kimmtrak<\/em>) which is used to treat adults with metastatic uveal melanoma (a type of intraocular melanoma<\/em>).\n<\/p>\n

\nTherapies Targeting CD19 Antigen are Likely to Dominate the CAR-T Therapy market During the Forecast Period<\/strong>\n<\/p>\n

\nBased on the type of target antigens, the T-cell therapy market is segmented into BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and others. Currently, therapies targeting CD19 antigen dominate the CAR-T therapies market, accounting for more than 65% of the overall market share. This dominance is primarily driven by the essential role of CD19 as it is a highly specific antigen expressed on B-cells, making it an ideal target for treating B-cell malignancies like leukemia and lymphoma.\n<\/p>\n

\nNorth America Accounts for the Largest Share of the overall TCR therapy Market<\/strong>\n<\/p>\n

\nNorth America is likely to capture the largest market share owing to the robust research and development infrastructure, a strong commercial base for cell therapies, and a high number of clinical trials being conducted in the region.\n<\/p>\n

\nHowever, it is worth noting that the market for TCR therapies in Asia-Pacific is expected to grow at a relatively faster pace (CAGR of more than 45%<\/em>), during the forecast period. This is driven by the increasing cases of cancer in the region, supported by the demand for curative treatments. Notably, it has been highlighted by industry experts that the cell therapy industry in China has witnessed growing interest from investment firms, enabling faster clinical research for T-cell therapies.\n<\/p>\n

\nKey T-Cell Therapy Market Insights<\/strong>\n<\/p>\n